Encouraging Results for Pembrolizumab in Head and Neck Cancer.
Abstract
Pembrolizumab achieved “remarkable” results in a phase 1 study of previously treated patients with recurrent, squamous-cell carcinoma of the head and neck, according to presenters at ASCO 2015.
Tumor shrinkage was observed in 57% of these heavily pretreated patients with poor prognosis, and 24.8% had a partial or complete response with treatment with pembrolizumab in an expansion cohort of the phase 1 KEYNOTE 012 trial.
Tanguy Y....
Paper Details
Title
Encouraging Results for Pembrolizumab in Head and Neck Cancer.
Published Date
Aug 1, 2015
Journal
Volume
8
Issue
Spec Issue
Pages
16 - 16
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History